Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy
- 1 January 2025
- journal article
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (02) , 597-619
Abstract
Non-small cell lung cancer (NSCLC) is a malignancy that faces serious resistance challenges in treatment. In this study, we identified Piperlongumine as a promising therapeutic candidate to overcome Osimertinib resistance in NSCLC. We systematically investigated the inhibitory effect of Piperlongumine on NSCLC cells and confirmed that it could effectively inhibit the in vitro kinase activity of wild-type (WT), exon 19 deletion, and L858R/T790M-mutated EGFR. We also found that Piperlongumine-induced intrinsic apoptosis by interfering with the EGFR signaling pathway, which was characterized by the down-regulation of the anti-apoptotic protein Mcl-1. Further mechanistic studies revealed that Piperlongumine-induced degradation of Mcl-1 was dependent on the Akt-GSK3β signaling pathway. Additionally, Piperlongumine-promoted interaction between Mcl-1 and β-TRCP, thereby enhancing β-TRCP-mediated ubiquitination and the degradation of Mcl-1. Furthermore, Piperlongumine significantly inhibited tumor growth in both Osimertinib-sensitive and resistant NSCLC xenograft models. These findings highlight the potential of Piperlongumine as an effective agent in overcoming EGFR-targeted therapy resistance and suggest new avenues for its clinical application in NSCLC treatment.Keywords
Funding Information
- Hunan Natural Science Foundation Outstanding Youth Fund (2023JJ10091)
- Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (BJ202203)
This publication has 39 references indexed in Scilit:
- Preparation of new green poly (amino amide) based on cellulose nanoparticles for adsorption of Congo red and its adaptive neuro-fuzzy modelingInternational Journal of Biological Macromolecules, 2024
- Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancerEuropean Journal of Medicinal Chemistry, 2024
- Top advances of the year: Targeted therapy for lung cancerCancer, 2024
- Piperlongumine and its derivatives against cancer: A recent update and future prospectiveArchiv der Pharmazie, 2024
- Gastrodin destabilizes survivin and overcomes pemetrexed resistanceCellular Signalling, 2023
- Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapyInternational Journal of Biological Macromolecules, 2021
- Overview of piperlongumine analogues and their therapeutic potentialEuropean Journal of Medicinal Chemistry, 2021
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistryMedicinal Research Reviews, 2018
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancerLung Cancer, 2015
- Clinical perspective of afatinib in non-small cell lung cancerLung Cancer, 2013